(MENAFN- EIN Presswire)
Frontotemporal Dementia Pipeline
Frontotemporal Dementia Pipeline
LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire / -- DelveInsight's,“Frontotemporal Dementia Pipeline Insight” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Frontotemporal Dementia Pipeline. Dive into DelveInsight's comprehensive report today! @ Frontotemporal Dementia Pipeline Outlook
Key Takeaways from the Frontotemporal Dementia Pipeline Report
.In December 2024:- Prevail Therapeutics:- Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.
.DelveInsight's Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
.The leading Frontotemporal Dementia Companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others
.Promising Frontotemporal Dementia Therapies such as LY3884963, DNL593, AL001, PBFT02, Olipudase alfa, and others
Stay ahead with the most recent pipeline outlook for Frontotemporal Dementia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Frontotemporal Dementia Treatment Drugs
Frontotemporal Dementia Emerging Drugs Profile
.AL001: Alector
AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. Alector Inc. is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.
.TPN-101: Transposon Therapeutics
TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.
.AVB-101: AviadoBio
AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families.
.VES001: Vesper Bio
VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for the neuro-cognitive disorder fronto-temporal dementia (FTD (GRN)). Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain.
Explore groundbreaking therapies and clinical trials in the Frontotemporal Dementia Pipeline. Access DelveInsight's detailed report now! @ New Frontotemporal Dementia Drugs
Frontotemporal Dementia Companies
Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
.Intra-articular
.Intraocular
.Intrathecal
.Intravenous
.Ophthalmic
.Oral
.Parenteral
.Subcutaneous
.Topical
.Transdermal
Frontotemporal Dementia Products have been categorized under various Molecule types such as
.Oligonucleotide
.Peptide
.Small molecule
Unveil the future of Frontotemporal Dementia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Frontotemporal Dementia Market Drivers and Barriers-
Scope of the Frontotemporal Dementia Pipeline Report
.Coverage- Global
.Frontotemporal Dementia Companies- Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
.Frontotemporal Dementia Therapies- LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
.Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
.Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Frontotemporal Dementia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Frontotemporal Dementia Companies, Key Products and Unmet Needs-
Table of Introduction
2 Dementia: Dementia– DelveInsight's Analytical Stage Products (Phase profiles in the detailed Stage Products (Phase Name: Company profiles in the detailed Stage Products (Phase I/II)
14 006 : Prevail profiles in the detailed and Discovery Stage Coya profiles in the detailed Dementia Key Dementia Key Dementia- Unmet Dementia- Market Drivers and Dementia- Future Perspectives and Dementia Analyst Dementia Key
List of Top Selling Market Research Reports in 2025
Varicose Vein Treatment Devices Market -
Vascular Access Devices Market -
Indwelling Catheters Market -
Healthcare Competitive Benchmarking -
Lymphoedema Market -
Pacemakers Market -
Myeloproliferative Neoplasms Market -
Surgical Mask & Respirator Market -
Nk Cell Therapy Market -
Novel Drug Delivery Devices Market -
Testicular Neoplasm Market -
Phototherapies For Psoriasis Market -
Skin Neoplasm Market -
Microscopy Device Market -
Bone Growth Stimulator Market -
Urea Cycle Disorders Market -
Antibody Drug Conjugate Market -
Penile Cancer Market -
Total Knee Arthroplasty Market -
Cardiac Implantable Electronic Devices Market -
Dyspepsia Market -
Lactose Intolerance Market -
Medical Marijuana Market -
Asperger Syndrome Market -
Catheter Stabilization Devices Market -
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yash Bhardwaj
DelveInsight
+91 96502 13330
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN20012025003118003196ID1109108753